744 related articles for article (PubMed ID: 26674305)
1. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.
Felker ER; Wu J; Natarajan S; Margolis DJ; Raman SS; Huang J; Dorey F; Marks LS
J Urol; 2016 May; 195(5):1421-1427. PubMed ID: 26674305
[TBL] [Abstract][Full Text] [Related]
2. The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
Amin A; Scheltema MJ; Shnier R; Blazevski A; Moses D; Cusick T; Siriwardena A; Yuen B; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
J Urol; 2020 May; 203(5):910-917. PubMed ID: 31825297
[TBL] [Abstract][Full Text] [Related]
3. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer.
Thompson JE; van Leeuwen PJ; Moses D; Shnier R; Brenner P; Delprado W; Pulbrook M; Böhm M; Haynes AM; Hayen A; Stricker PD
J Urol; 2016 May; 195(5):1428-1435. PubMed ID: 26529298
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
5. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
6. A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
Pal RP; Ahmad R; Trecartan S; Voss J; Ahmed S; Bazo A; Lloyd J; Walton TJ
J Urol; 2018 Aug; 200(2):302-308. PubMed ID: 29477717
[TBL] [Abstract][Full Text] [Related]
7. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
8. Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
Doan P; Scheltema MJ; Amin A; Shnier R; Geboers B; Gondoputro W; Moses D; van Leeuwen PJ; Haynes AM; Matthews J; Brenner P; O'Neill G; Yuen C; Delprado W; Stricker P; Thompson J
J Urol; 2022 Nov; 208(5):1028-1036. PubMed ID: 35947521
[TBL] [Abstract][Full Text] [Related]
9. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.
Hsiang W; Ghabili K; Syed JS; Holder J; Nguyen KA; Suarez-Sarmiento A; Huber S; Leapman MS; Sprenkle PC
Eur Urol Focus; 2021 Jan; 7(1):47-54. PubMed ID: 31147263
[TBL] [Abstract][Full Text] [Related]
11. Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience.
Shoji S; Hiraiwa S; Endo J; Hashida K; Tomonaga T; Nakano M; Sugiyama T; Tajiri T; Terachi T; Uchida T
Int J Urol; 2015 Feb; 22(2):173-8. PubMed ID: 25316213
[TBL] [Abstract][Full Text] [Related]
12. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
13. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
14. Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.
Bryk DJ; Llukani E; Huang WC; Lepor H
J Urol; 2015 Nov; 194(5):1234-40. PubMed ID: 26003206
[TBL] [Abstract][Full Text] [Related]
15. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.
Frye TP; George AK; Kilchevsky A; Maruf M; Siddiqui MM; Kongnyuy M; Muthigi A; Han H; Parnes HL; Merino M; Choyke PL; Turkbey B; Wood B; Pinto PA
J Urol; 2017 Mar; 197(3 Pt 1):640-646. PubMed ID: 27613356
[TBL] [Abstract][Full Text] [Related]
16. Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?
Abd-Alazeez M; Ahmed HU; Arya M; Allen C; Dikaios N; Freeman A; Emberton M; Kirkham A
Urol Oncol; 2014 Aug; 32(6):741-7. PubMed ID: 24981993
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
[TBL] [Abstract][Full Text] [Related]
18. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study.
Ullrich T; Arsov C; Quentin M; Mones F; Westphalen AC; Mally D; Hiester A; Albers P; Antoch G; Schimmöller L
Eur Radiol; 2020 Nov; 30(11):6042-6051. PubMed ID: 32591887
[TBL] [Abstract][Full Text] [Related]
20. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]